LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 20 of 66
Next
>>
>
476 to 500 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Trametinib	180615_MC_08	1098	0.0672	48	29	10	5	Trametinib	0.031603332	treatment	72	1	MCF10A-GM_8	77	0.0655	586.3	196.0	12428	298.5	0.0234	0.04213	0.1531
Trametinib	180615_MC_08	1228	0.0940	81	42	11	10	Trametinib	0.031603332	treatment	72	1	MCF10A-GM_9	123	0.0910	586.3	196.0	12428	298.5	0.0234	0.06765	0.1827
Trametinib	180615_MC_06	1010	0.0632	34	32	4	17	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_1	66	0.0613	586.3	196.0	12428	298.5	0.0234	0.03794	0.1314
Trametinib	180615_MC_06	873	0.0716	21	43	8	13	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_2	64	0.0683	586.3	196.0	12428	298.5	0.0234	0.04490	0.0946
Trametinib	180615_MC_06	1086	0.0739	37	46	11	10	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_3	83	0.0710	586.3	196.0	12428	298.5	0.0234	0.04760	0.1502
Trametinib	180615_MC_07	806	0.1095	43	50	4	22	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_4	93	0.1034	586.3	196.0	12428	298.5	0.0234	0.08005	0.0749
Trametinib	180615_MC_07	1095	0.1367	90	72	8	12	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_5	162	0.1289	586.3	196.0	12428	298.5	0.0234	0.10548	0.1523
Trametinib	180615_MC_07	991	0.0742	33	43	14	7	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_6	76	0.0712	586.3	196.0	12428	298.5	0.0234	0.04783	0.1265
Trametinib	180615_MC_08	847	0.1444	81	53	6	13	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_7	134	0.1366	586.3	196.0	12428	298.5	0.0234	0.11320	0.0871
Trametinib	180615_MC_08	921	0.1228	64	57	8	9	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_8	121	0.1161	586.3	196.0	12428	298.5	0.0234	0.09272	0.1080
Trametinib	180615_MC_08	834	0.1010	57	33	10	21	Trametinib	0.099799981	treatment	72	1	MCF10A-GM_9	90	0.0974	586.3	196.0	12428	298.5	0.0234	0.07400	0.0833
Trametinib	180615_MC_06	920	0.1249	81	44	3	20	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_1	125	0.1196	586.3	196.0	12428	298.5	0.0234	0.09622	0.1077
Trametinib	180615_MC_06	815	0.0905	25	51	4	3	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_2	76	0.0853	586.3	196.0	12428	298.5	0.0234	0.06190	0.0776
Trametinib	180615_MC_06	940	0.0675	23	42	8	5	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_3	65	0.0647	586.3	196.0	12428	298.5	0.0234	0.04128	0.1131
Trametinib	180615_MC_07	684	0.1320	43	53	6	22	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_4	96	0.1231	586.3	196.0	12428	298.5	0.0234	0.09968	0.0356
Trametinib	180615_MC_07	1059	0.0731	21	58	7	10	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_5	79	0.0694	586.3	196.0	12428	298.5	0.0234	0.04602	0.1436
Trametinib	180615_MC_07	785	0.1094	47	44	10	19	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_6	91	0.1039	586.3	196.0	12428	298.5	0.0234	0.08048	0.0685
Trametinib	180615_MC_08	929	0.1150	45	67	8	3	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_7	112	0.1076	586.3	196.0	12428	298.5	0.0234	0.08419	0.1101
Trametinib	180615_MC_08	943	0.1131	65	49	8	13	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_8	114	0.1079	586.3	196.0	12428	298.5	0.0234	0.08445	0.1139
Trametinib	180615_MC_08	891	0.1177	52	59	11	8	Trametinib	0.319359801	treatment	72	1	MCF10A-GM_9	111	0.1108	586.3	196.0	12428	298.5	0.0234	0.08738	0.0997
Trametinib	180615_MC_06	769	0.1676	84	59	8	16	Trametinib	0.998	treatment	72	1	MCF10A-GM_1	143	0.1568	586.3	196.0	12428	298.5	0.0234	0.13340	0.0635
Trametinib	180615_MC_06	868	0.0766	33	36	9	11	Trametinib	0.998	treatment	72	1	MCF10A-GM_2	69	0.0736	586.3	196.0	12428	298.5	0.0234	0.05024	0.0932
Trametinib	180615_MC_06	854	0.0802	31	40	9	21	Trametinib	0.998	treatment	72	1	MCF10A-GM_3	71	0.0768	586.3	196.0	12428	298.5	0.0234	0.05336	0.0891
Trametinib	180615_MC_07	880	0.1082	63	39	8	10	Trametinib	0.998	treatment	72	1	MCF10A-GM_4	102	0.1039	586.3	196.0	12428	298.5	0.0234	0.08047	0.0966
Trametinib	180615_MC_07	895	0.1006	39	55	8	21	Trametinib	0.998	treatment	72	1	MCF10A-GM_5	94	0.0950	586.3	196.0	12428	298.5	0.0234	0.07165	0.1008

|<
<<
Previous
Page 20 of 66
Next
>>
>
476 to 500 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)